Evidence map›Paper›PMID 28456850›Full record

ArticleAnnals of hematology2017

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.

Lukas Weiss, Thomas Melchardt, Alexander Egle, Georg Hopfinger, Hubert Hackl, Richard Greil, Juergen Barth, Mathias Rummel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lukas WeissSalzburg Cancer Research Institute, Department of Internal Medicine III, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria. lu.weiss@salk.at.ORCID http://orcid.org/0000-0002-2174-5613
Thomas MelchardtSalzburg Cancer Research Institute, Department of Internal Medicine III, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
Alexander EgleSalzburg Cancer Research Institute, Department of Internal Medicine III, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
Georg HopfingerDepartment of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Hubert HacklDivision of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.
Richard GreilSalzburg Cancer Research Institute, Department of Internal Medicine III, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
Juergen BarthMedizinische Klinik IV, Hospital of the Justus-Liebig-University, Giessen, Germany.
Mathias RummelMedizinische Klinik IV, Hospital of the Justus-Liebig-University, Giessen, Germany.
Paracelsus Medical University · ATJustus-Liebig-Universität Gießen · DEInnsbruck Medical University · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a well-known risk factor for the development of cancer, but its influence on the course of disease is still controversial. We investigated the influence of body mass index (BMI) on overall survival (OS) in 502 patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma in a subgroup analysis of the StiL (Study Group Indolent Lymphomas) NHL1 trial. We defined a cut-off of 22.55 kg/m

Indexed as

Body Mass IndexAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansLogistic ModelsLymphoma, Mantle-CellLymphoma, Non-HodgkinMaleMiddle AgedMultivariate AnalysisOutcome Assessment, Health CareProportional Hazards ModelsBMIBody mass indexB-symptomsLymphomaNHLPrognosis

Identifiers

PMID28456850
PMCPMC5486799
OpenAlexW2608226316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.